Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02237898 · ClinicalTrials.gov registry record · Phase 1

Harnessing the Power of Technology: MOMBA for Postpartum Smoking

A Phase 1 study of Smoking Cessation, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
26
Enrollment target
1
Study location

NCT02237898 is a Phase 1 study of Smoking Cessation that has completed, run by Yale University. The registered enrollment target is 26 participants, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02237898, a Phase 1 study of Smoking Cessation, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
26 participants
Enrollment target
1
Study location

Study Summary

Through a smartphone platform, financial incentives for smoking abstinence in postpartum women can be delivered remotely, thus minimizing the need for participants to come to the office to receive traditional contingency management.

Conditions Studied

Interventions

  • BEHAVIORAL MoMba Live Long app & Sensordrone™ carbon-monoxide sensor
  • BEHAVIORAL Office contingency management
  • DEVICE Sensordrone™ carbon-monoxide sensor
  • DEVICE MoMba Live Long Smartphone application

Study Locations (1)

Connecticut

  • Center for Wellbeing of Women and Mothers, 40 Temple Street, Ste 6B, Yale University - New Haven

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2017-02-10
Est. Completion 2019-05-13
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT02237898

The ClinicalTrials.gov registry entry for NCT02237898 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 475-participant average among 188 other Smoking Cessation trials with a reported enrollment target (95% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 4 interventions - of which MoMba Live Long app & Sensordrone™ carbon-monoxide sensor is the first listed.

NCT02237898 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT02237898 about?

NCT02237898 is a clinical study titled "Harnessing the Power of Technology: MOMBA for Postpartum Smoking". Through a smartphone platform, financial incentives for smoking abstinence in postpartum women can be delivered remotely, thus minimizing the need for participants to come to the office to receive traditional contingency management.

What is the current status of trial NCT02237898?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-02-10. Estimated completion is 2019-05-13.

What conditions does trial NCT02237898 study?

This clinical trial studies the following conditions: Smoking Cessation.

What interventions are being tested in trial NCT02237898?

The interventions under investigation include: MoMba Live Long app & Sensordrone™ carbon-monoxide sensor (BEHAVIORAL), Office contingency management (BEHAVIORAL), Sensordrone™ carbon-monoxide sensor (DEVICE), MoMba Live Long Smartphone application (DEVICE).

Who is sponsoring clinical trial NCT02237898?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02237898 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.